August 5, 2020
The National Institutes of Health will soon launch a Phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
November 19, 2024
The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclonal antibody, and durvalumab, an immune checkpoint inhibitor.
January 23, 2013
…to understanding and developing treatments for shock, sepsis and multiorgan failure. Collectively, these maladies represent a major unmet medical need: they are the number one cause of mortality in intensive care units in the United States, with hundreds of thousands of deaths annually. There is currently no treatment for these…
June 27, 2018
Scientists have long pondered how non-living materials coalesced into the earliest life forms on Earth. Nearly 60 years ago Stanley Miller and Harold Urey, founding professors of the physical sciences at the University of California San Diego, established a tradition of working to answer questions about life’s molecular origins. Professor…
October 11, 2023
University of California San Diego cancer biologist Tatiana Hurtado de Mendoza has been named the recipient of the 2023 Claugus Award for Medical Research. The award was established in 2021 by the Foundation For A Better World.
June 25, 2015
Two of the nation’s leading physician-scientists in the search to better understand and treat Alzheimer’s disease – William Mobley, MD, PhD, and Michael Rafii, MD, PhD – have been named interim co-directors of the Alzheimer’s Disease Cooperative Study (ADCS), a major initiative formed in 1991 as a cooperative agreement between…
May 15, 2020
The NIH has launched a major clinical trial to assess the malaria drug hydroxychloroquine and antibiotic azithromycin as a treatment for COVID-19. The trial will recruit 2,000 participants at 30 sites. A Q&A with the trial’s team leader: Davey Smith, MD, of UC San Diego School of Medicine.
August 2, 2022
Researchers report that a gene therapy approach, developed at UC San Diego measurably delayed disease onset in humanized mouse and rat models of familial ALS, an inherited form of the disease that runs in families.
July 20, 2018
The governing board of the California Institute for Regenerative Medicine (CIRM) unanimously approved this week two grants worth more than $2.2 million to University of California San Diego School of Medicine researchers investigating stem cell-based therapies for a rare genetic disorder that affects the heart and a chronic, progressive affliction…
December 12, 2022
UC San Diego Health has been awarded the prestigious 2022 California Association of Public Hospitals and Health Systems Quality Leaders Award in the category of health equity.
